Setsuro Tech Inc. is a biotech startup that originated from Tokushima University and was founded in 2017. The company’s mission is to “create industries that solve your and the planet’s problems by harnessing from the potential of living organisms”. Our company provides innovative genome editing technology and contributes to the advancement of industry and human health and well-being. We use proprietary technologies to provide contract genome editing R&D services to researchers in academia and industry. Our goal is to provide genome-edited organisms broadly available to society and to advance the genome editing industry. The name of our service, PAGEs, stands for Platform App(lication) using Genome Editing by Setsuro Tech. We named it with the idea that “genome editing will add new pages to all industries worldwide and bring about a revolution in the genome editing industry”. With PAGEs, Setsuro Tech’s genome editing technology can be used to develop new traits in a wide range of species and produce useful and valuable substances. Regardless of the size of the company or the scope of the business or industry, Setsuro Tech’s PAGEs are creating breakthroughs in current production systems and providing solutions to social and environmental problems.
ScienceTrack
ScienceTrack is a Czech startup on a mission to modernize laboratory animal research with intuitive, data-driven software. From colony management to resource scheduling, our solutions streamline daily workflows, improve compliance, and support better science. Our flagship products include ZETA, a powerful animal colony management platform, and ReservAnt, a flexible tool for booking equipment, spaces, and personnel in research facilities. With user-centered design and seamless integration, ScienceTrack empowers labs to focus more on discovery and less on administration. Visit our booth to experience a live demo and learn how ScienceTrack is shaping the future of animal facility operations.
Sante Science
Sante Science is a biotech/foodtech that has developed an innovative biotechnology through upcycling to produce natural ingredients that enhance treatment and reduce the oncological chemotherapy side effects in pets and humans, improving quality of life, longevity, gut and immune health.
SAGITTA BIOTECH
Sagitta biotech is a preclinical-stage Biotech Company developing vaccines against infectious diseases and cancer. Our proprietary viral vaccine platform is based on a highly modified Measles vaccines and gave us the ability to quickly develop vaccines with a very good B and T cell response, which are safe, and are produced using a process which is identical for all pathogens (“true” vaccine platform). Sagitta is developing its own products, which will enter clinical at the end of 2025, and we are open to collaborations and co-developments on new indications. | Sagitta biotech is developping vaccines against infectious diseases and cancer from an innovative platform combining viral vectors and mRNA. The benefits of the platform are : -Very good immunogenicity (humoral and cellular) and long term protection -High safety -The manufacuring process is constant (identical for all vaccines), allowing significant shortcuts during development -The platform productivity is very high (one million dose per week from a 1 liter bioreactor, for our influenza vaccine candidate). The company is developing its own pipeline of assets, but is open to collaboration and co-development.
Royalmount Laboratories
Royalmount Labs now employs over 45 scientific, technical and support staff, and occupies 8000 sq ft of purpose built laboratory and office space. We have the latest state-of-the-art instrumentation including 13 LC-MS/MSs, 2 multimode spectrophotometer plate readers, a Luminex and 2 robotic liquid handling systems. As a partner of choice for many pharma, biotech and virtual companies, we have a very high rate of repeat business, and this is a testament to our three core principles that we consistently deliver on to our clientele – Scientific Excellence; Customer Service; On-time Delivery. With our unparalleled expertise and customized solutions, we can help you elevate your drug development process to the next level. Whether you need bioanalysis or pharmacokinetic analysis, we have the right team and the right tools. Don’t settle for less, choose Royalmount Laboratories as your partner for your drug development programs.
ROTOR CLIP CO.
Rotor Clip is the only manufacturer of every retaining ring style (circlips, snap rings, spiral rings), wave springs & hose clamps. Whether it’s standard or custom, stamped or coiled, our team ensure you have the right part, in the right material for your application every time. With billions of parts produced and shipped annually, our team of engineers is focused on providing Application Driven Solutions™. With manufacturing in the USA & Europe, as well as an extensive network of global warehouses and distribution partners, we’re able to supply and meet our customer’s production requirements and timelines worldwide. | We are the global leader in the manufacturer of Retaining Rings, Wave Springs and Hose Clamps. With over 20,000 standard parts, we specialize in engineering the right part, for the right application, every time; whether it is a standard or custom. | Rotor Clip is the global leader in the manufacturer of Retaining Rings, Wave Springs and Hose Clamps. With over 20,000 standard parts, we specialize in engineering the right part, for the right application every time whether it is a standard or custom. • Retaining Rings: Rotor Clip provides the widest selection of tapered section, constant section, and spiral retaining rings in the world. Coiled or Stamped, we’ll provide you with the best solution for your application • Wave Springs: Rotor Clip manufactures both standard and custom wave springs that can reduce spring heights by up to 50%. At Rotor Clip we provide materials that can sustain even the harshest of environments. At Rotor Clip, we provide Application Driven Solutions™. | Global Leading Manufacturer — 100% Produced In-House Giving You Higher Quality, Shorter Lead Times, & Lower Final Costs. Free Technical Support, Engineer Consulting, Samples & More! | Rotor Clip Co. is a leader in the manufacture of tapered, constant section, and spiral retaining rings meeting DIN, inch, ANSI metric, and JIS standards, as well as Truwave wave springs, Rotor Clamp hose clamps, and custom designs. The company supports the market with first-class engineering know-how, expert advice, reliability of delivery, and high-quality products. Rotor Clip is certified to ISO 9001, TS 16949, AS9100, and ISO 14001. | Rotor Clip is the only manufacturer of every retaining ring style (circlips, snap rings, spiral rings), wave springs & hose clamps. Whether it’s standard or custom, stamped or coiled, our team ensure you have the right part, in the right material for your application, every time.
Ronawk, Inc.
Ronawk’s Bio-Blocks™ platform is a proprietary 3D bioprinted hydrogel system designed to replicate physiologic microenvironments with exceptional fidelity. It supports the growth and organization of over 80 cell types including primary cells, explants, and co-cultures, enabling tissue-mimetic architecture. Ronawk is advancing a pipeline that includes wound healing, regenerative medicine applications, and immune and stem cell expansion.
QUANTOOM BIOSCIENCES
Quantoom Biosciences, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production. Quantoom’s approach to the production of mRNA vaccines involves redesigning the entire manufacturing process from start to finish. By doing this, Quantoom Biosciences can produce mRNA vaccines faster, more efficiently, and at a lower cost than traditional methods. | Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and NcapsulateTM for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
PrecisemAb Biotech Co., Ltd.
PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. [Features of Core Technology (Antibody Lock)] ‧Higher masking ability and removal ability ‧Low immunogenicity ‧Prevention of anti-drug antibody binding ‧Prolonged serum half-life [Lead Product] PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. [Partnering] Through the (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials. | PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. | Company Overview Founded in October 2021, PrecisemAb Biotech was established by the late Professor Tian-Lu Cheng, former Vice President of Kaohsiung Medical University (KMU), as a KMU spin-off company. PrecisemAb focuses on applying the exclusively licensed Universal Antibody Lock Technology to develop next-generation precision antibody drugs with high specificity, low side effects, and enhanced therapeutic efficacy. Innovations & Advantages of the Universal Antibody Lock Platform The Universal Antibody Lock Technology integrates a Hinge + Linker structure that connects the VL/VH domains of an antibody. This unique design prevents antibodies from binding to healthy tissues until they reach the tumor microenvironment (TME). The Hinge-based lock, derived from human IgG1, serves as a masking mechanism, reducing unwanted interactions with normal tissues. The Linker, optimized through computational modeling, includes tumor-specific protease cleavage sites and spatial adjustment regions that ensure precise activation in the tumor microenvironment (TME). This mechanism enables antibodies to remain inactive in normal tissues and only activate when exposed to tumor-specific proteases, thereby minimizing off-target toxicity and enhancing therapeutic efficacy. By selectively triggering antibody activation at the tumor site, this technology significantly reduces side effects and improves treatment outcomes, ultimately enhancing patient quality of life. Compared to competing platforms, the Universal Antibody Lock Technology offers several key advantages. First, the human IgG1 hinge-based lock has low immunogenicity, reducing the risk of anti-drug antibody (ADA) formation and avoiding interference with drug efficacy. Second, the platform is highly versatile, allowing seamless integration into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs), which accelerates the development timeline for Lock-antibody drugs. Third, the linker design, incorporating tumor-specific protease cleavage sites and spatial adjustment regions, delivers the highest antibody activation rate globally in TME. The Universal Antibody Lock Technology has been adopted for industry collaboration. In May 2024, GlycoNex Biotech signed a non-exclusive licensing agreement with PrecisemAb, further demonstrating its applicability in antibody drug development. Drug Development (1) PrecisemAb’s lead drug, PSM101 (Lock-EGFR antibody), is designed for EGFR-expressing cancers, including head and neck cancer and colorectal cancer. The drug has successfully completed in vitro and in vivo efficacy and safety studies, cell line development, upstream process optimization (yield: 4.2 g/L), downstream process optimization, formulation research, and accelerated stability testing. PSM101 is planned for IND submission to the US FDA and TFDA in Q4 2026. (2) Additionally, PSM915 (Lock-TNF-α) has been evaluated in Biomedcode’s rheumatoid arthritis (RA) mouse model, demonstrating its ability to suppress RA disease progression and improve drug safety.